HealthDay News — For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with the risk of developing nonarteritic anterior ischemic optic ...

CMTX-101 is an investigational immune-enabling antibody designed to target and destroy the pro-inflammatory structure of bacteria biofilms.

The prevalence of disorders of the gut-brain interaction (DGBI) increased from before to after the COVID-19 pandemic, according to a study published online in C ...

When President Donald Trump signed a law adding work requirements for some Medicaid recipients, he may have undercut lawmakers in at ...

HealthDay News — Just under half of patients receiving an abnormal blood-based colorectal cancer screening test result receive a follow-up colonoscopy (FU-CY) within 6 months, according to a study ...

Designating GG1 on biopsy as noncancer without considering the prognostic values of adverse clinical features may lead to undertreatment and an increased risk of cancer-specific death in men with ...

Flu-linked ANE is associated with high morbidity and mortality in young and previously healthy children. The findings emphasize the need for prevention, early recognition, intensive treatment, and ...

The findings not only demonstrate the number of legal barriers faced by various sociodemographic groups but also highlight vulnerable populations with greater need of legal navigation, informing ...

The Food and Drug Administration (FDA) is requiring class-wide label changes for opioid medications to provide additional information on the risks associated with long-term use.

Meta-analysis of 10 studies indicate an average TTD of 3.5 years across all dementia types, with younger age at onset and frontotemporal dementia associated with longer diagnostic intervals.

Critics of most-favored-nation drug pricing have warned that it could reduce patient access to certain drugs, raise the prices of other drugs, and decrease research and development for new drugs.

These findings may partially reflect both structural barriers that delay timely diagnosis and the impact of local equity-driven initiatives that broaden colorectal cancer screening access.